At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 235 enrolled
Drug / intervention
MT10109L +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
In Brief
A Phase 3 clinical trial evaluating MT10109L and Placebo for Lateral Canthal Lines. Completed, enrolled 235 participants across 14 sites in 3 countries.
Detailed Summary
To evaluate the safety and efficacy of MT10109L in the treatment of lateral canthal lines (LCL) in participants with moderate to severe LCL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Canthal Lines
CountriesRussia, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedDec 2018
Primary CompletionFeb 2020
Study CompletionJan 2021
TodayJul 2026
First PostedDec 24, 2018
Enrollment StartDec 20, 2018
Primary CompletionFeb 27, 2020
Study CompletionJan 25, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.5 years ago
Interventions
MT10109Ldrug
MT10109L will be injected into the LCL.
Placebodrug
Placebo will be injected into the LCL.